Sitemap
Pages
Posts
- News
- EMUC20 and COVID-19
- 12th EMUC celebrates longstanding ties between societies
- Imaging and pathology: The harm of false positives
- ARAMIS likely to change Guidelines recommendations
- EMUC19 sums up GU cancer reports from APCCC, ESUI19, EAURF and PRIAS
- HoT courses highlight MRI reading and fusion biopsy
- Early detection of prostate cancer: a multidisciplinary look
- ESUP Symposium examines the potential of liquid biopsies in uro-oncology
- Urine biomarkers may detect disease state in NMIBC
- Trial presentations to have “Guideline-changing potential”
- What to do when faced with a nightmare PCa case
- Keeping EMUC19 relevant for young onco-urology specialists
- EMUC18 addresses current dilemmas in mPCa treatment
- Video: Update on POUT Trial
- Video: Radiomics: Images are more than pictures
- EMUC18 grants recognition to promising urologists
- New developments in PCa evaluation: Pathology & Radiomics
- Progress updates of notable trials at EMUC18: What you need to know
- Video: Update on PROSPER & SPARTAN Trials
- Identifying the frail kidney cancer patient
- Video: Sequencing of novel therapies in urogenital malignancies
- Deliberations on IO as first-line therapy for kidney cancer patients
- Video: Update on EAU Prostate Cancer Center consensus meeting
- Video: Prostate cancer management: Implementation without good evidence?
- The future of good evidence gathering for PCa
- PCa management essentials opens EMUC’s 10th year
- ESUP Symposium: a multidisciplinary look at the future of bladder cancer treatment
- Birtle to present key POUT findings and updates at EMUC18
- EMUC18: Everything in prostate cancer pathology you were afraid to ask
- EMUC18: Joint initiatives reinforce effective MDT in onco-urology
- EMUC18: Costs and optimal PCa care- Finding the crucial balance
- EMUC18: MDT work is crucial for optimal management of urological cancers
- Improving reporting systems, defining selection criteria in PCa diagnosis
- EMUC17: Using biomarkers in decision-making for RCC treatment
- EMUC17: Bladder cancer- Challenges in immunotherapy
- EMUC17: Crucial need to standardize MRI use and reporting
- EMUC17: Examining key topics in urothelial carcinoma
- FALCON Workshop focuses on salvage intra-prostatic relapses
- EMUC16: National cancer plans – Key element in cancer prevention
- EMUC16: High sensitivity urine biomarkers to detect bladder cancer
- EMUC16: Active Surveillance for early PCa: Impact of new technology
- EMUC16: Impact of sports and lifestyle on uro-oncology
- EMUC16: In Focus: Consequences of pelvic radiotherapy
- EMUC16 grants awards to promising research
- EMUC16: Kidney cancer: From diagnosis to progression
- EMUC16: Imaging-guided approaches for PCa recurrences
- EMUC16: Combination therapies in prostate cancer
- EMUC16: Trends in genitourinary pathology and impact on clinical practice
- EMUC16: Early cancer detection strategies can ease healthcare disparities in Europe
- EMUC16: Indolent cancers: The fine art of sophisticated pathology
- EMUC16: Managing recurrent PCa: Has focal therapies come of age?
- EMUC16: Refined patient selection is crucial to improve impact of chemotherapy for bladder cancer patients
- EMUC16: Impact of new technologies on cancer management
- Higher abstract submission record for EMUC16
- Uropathology training workshop in Milan
- [Video] Reasons not to miss EMUC17